Buyback yield (TTM)
0.78%
Shareholder yield (TTM)
4.61%
5Y share count change
0.5%
Buyback spend (TTM)
$827.00M
Cumulative buybacks
$2.42B
Key takeaways
- CME Group (CME) repurchased about $827.00M of stock over the trailing twelve months.
- Diluted share count is roughly flat (0.5%) over the last ~5 fiscal years — buybacks are offsetting dilution but not shrinking the float.
- TTM buyback ÷ stock-based-comp ratio of 8.67× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +45.1% per year over the latest 5-year window.
- TTM repurchases used about 311% of free cash flow remaining after dividends.
Dividend & buyback yield over time for CME Group (CME)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for CME Group (CME)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for CME Group (CME)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for CME Group (CME)
Latest: $266.10M
Overview
CME Group (CME) most recent annual buyback spend stands at $266.10M (2025) – surged 706.4% year-over-year.
CME Group buyback spend has grown for 2 consecutive years, with a +45.1% compound annual growth rate over 2020–2025 (5 years).
CME Group buyback spend plunged from $949.34M in 2007 to $266.10M in 2025, a 72.0% drawdown.
2007 marks the peak buyback spend at $949.34M, with the historical low of $0.00 recorded in 2000.
CME Group Buyback Spend 2025: $266.10M
In 2025, CME Group reported buyback spend of $266.10M, surged 706.4% from 2024.
CME Group Buyback Spend 2024: $33.00M
CME Group buyback spend in 2024 was $33.00M, surged 54.2% from 2023.
CME Group Buyback Spend 2023: $21.40M
2023's buyback spend for CME Group came in at $21.40M, declined 13.7% below 2022.
CME Group Buyback Spend 2022: $24.80M
CME Group buyback spend in 2022 was $24.80M.
CME Group Buyback Spend 2021: $0.00
CME Group buyback spend in 2021 was $0.00.
See more financial history for CME Group (CME).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $266.10M | $94.80M | $171.30M | 0.27% | 0.36B | +0.1% | |
| 2024 | $33.00M | $89.50M | −$56.50M | 0.04% | 0.36B | +0.1% | |
| 2023 | $21.40M | $82.90M | −$61.50M | 0.03% | 0.36B | +0.1% | |
| 2022 | $24.80M | $84.30M | −$59.50M | 0.04% | 0.36B | +0.1% | |
| 2021 | $0.00 | $75.20M | −$75.20M | — | 0.36B | +0.1% | |
| 2020 | $41.40M | $96.00M | −$54.60M | 0.06% | 0.36B | +0.1% | |
| 2019 | $36.80M | $73.10M | −$36.30M | 0.05% | 0.36B | +4.2% | |
| 2018 | $0.00 | $96.50M | −$96.50M | — | 0.34B | +1.0% | |
| 2017 | $0.00 | $58.00M | −$58.00M | — | 0.34B | +0.4% | |
| 2016 | $0.00 | $66.20M | −$66.20M | — | 0.34B | +0.3% | |
| 2015 | $0.00 | $60.80M | −$60.80M | — | 0.34B | +0.5% | |
| 2014 | $0.00 | $54.80M | −$54.80M | — | 0.34B | +0.5% | |
| 2013 | $0.00 | $54.40M | −$54.40M | — | 0.33B | +0.6% | |
| 2012 | $0.00 | $61.40M | −$61.40M | — | 0.33B | -0.4% | |
| 2011 | $220.40M | $51.30M | $169.10M | 1.37% | 0.33B | +0.4% | |
| 2010 | $575.30M | $40.90M | $534.40M | 2.68% | 0.33B | -0.1% | |
| 2009 | $27.00M | $33.40M | −$6.40M | 0.12% | 0.33B | +12.9% | |
| 2008 | $224.03M | $0.00 | $224.03M | 1.80% | 0.29B | +33.7% | |
| 2007 | $949.34M | $22.85M | $926.49M | 2.90% | 0.22B | +25.6% | |
| 2006 | $0.00 | $16.36M | −$16.36M | — | 0.18B | +0.8% | |
| 2005 | $0.00 | $0.00 | $0.00 | — | 0.17B | +1.2% | |
| 2004 | $0.00 | $0.00 | $0.00 | — | 0.17B | +1.4% | |
| 2003 | $0.00 | $0.00 | $0.00 | — | 0.17B | +12.9% | |
| 2002 | $0.00 | $0.00 | $0.00 | — | 0.15B | +2.7% | |
| 2001 | $0.00 | $0.00 | $0.00 | — | 0.15B | +1.7% | |
| 2000 | $0.00 | $0.00 | $0.00 | — | 0.14B | — |
- 2025$266.10M
- 2024$33.00M
- 2023$21.40M
- 2022$24.80M
- 2021$0.00
- 2020$41.40M
- 2019$36.80M
- 2018$0.00
- 2017$0.00
- 2016$0.00
- 2015$0.00
- 2014$0.00
- 2013$0.00
- 2012$0.00
- 2011$220.40M
- 2010$575.30M
- 2009$27.00M
- 2008$224.03M
- 2007$949.34M
- 2006$0.00
- 2005$0.00
- 2004$0.00
- 2003$0.00
- 2002$0.00
- 2001$0.00
- 2000$0.00
Buybacks vs stock-based compensation for CME Group (CME)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 8.67×.
Buybacks vs dividends (share of cash returned) for CME Group (CME)
How CME Group splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as CME Group, ranked by their latest buyback spend.
| $34.59B | |
| $24.10B | |
| $19.52B | |
| $13.39B | |
| $12.36B | |
| $11.73B | |
| $5.83B | |
| $0.00 |
- $34.59B
- $24.10B
- $19.52B
- $13.39B
- $12.36B
- $11.73B
- $5.83B
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $266.10M (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation